IUIS 2025

Myllia’s Director of R&D, Anke Loregger, will be presenting our CRISPR-based VISTA platform for unbiased target discovery in primary myeloid cells at IUIS 2025. Are you interested in I&I target ID/validation, e.g., in primary human macrophages and dendritic cells? We’ve mastered pooled, scalable CRISPR screens with scRNA-Seq in these primary myeloid cell types, so get in touch to learn more!

Event website:
IUIS 2025

Attendee(s):
Anke Loregger (LinkedIn)